dixit
★    

India,
2011-06-06 09:29
(5502 d 14:27 ago)

Posting: # 7070
Views: 6,344
 

 Potency difference [Regulatives / Guidelines]

Dear All,

Many of the regulatory bodies specify that the potency between the test and reference products should not differ more than 5%. Can any one please let me know what would be the impact in a bio equivalence study if the difference is more.


Regards,

DIXIT.
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2011-06-06 16:54
(5502 d 07:01 ago)

@ dixit
Posting: # 7078
Views: 5,640
 

 Which country?

Dear Dixit,

the subject lines tells it all. I don’t want to go through all different regulations, but will be happy doing so if you give us more information.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
dixit
★    

India,
2011-06-07 09:02
(5501 d 14:53 ago)

@ Helmut
Posting: # 7083
Views: 5,611
 

 EU

Dear Helmut,

Here is the reference.

The assayed content of the batch used as test product should not differ more than 5% from that of the batch used as reference product determined with the test procedure proposed for routine quality testing of the test product.

Regards,
DIXIT.


Edit: Subject line changed, reference linked; see here. [Helmut]
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2011-06-07 14:59
(5501 d 08:56 ago)

@ dixit
Posting: # 7090
Views: 5,774
 

 EU: content correction – if justified!

Dear Dixit!

You dropped and essential part in quoting Section 4.1.2:

Unless otherwise justified, the assayed content of the batch used as test product should not differ more than 5% from that of the batch used as reference product determined with the test procedure proposed for routine quality testing of the test product. The Applicant should document how a representative batch of the reference product with regards to dissolution and assay content has been selected.

For an acceptable justification see the GL Section 4.1.8:

In bioequivalence studies, the pharmacokinetic parameters should in general not be adjusted for differences in assayed content of the test and reference batch. However, in exceptional cases where a reference batch with an assay content differing less than 5% from test product cannot be found (see section 4.1.2) content correction could be accepted. If content correction is to be used, this should be pre-specified in the protocol and justified by inclusion of the results from the assay of the test and reference products in the protocol.

(my emphases)

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
raghu
★    

India,
2011-06-07 12:47
(5501 d 11:08 ago)

@ dixit
Posting: # 7087
Views: 5,606
 

 Potency difference

Dear Dixit,

The assayed content should not differ more than 5% b/w test and reference batch.

If it is present, the BE study should not be performed.

The regulatory authorities will not accept BE study with the difference of 5% b/w test and reference batch.

Regards
Raghavender.
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2011-06-07 15:26
(5501 d 08:29 ago)

@ raghu
Posting: # 7093
Views: 5,625
 

 Not for the FDA

Dear Raghavender!

❝ The assayed content should not differ more than 5% b/w test and reference batch.


❝ If it is present, the BE study should not be performed.


False in many countries. See above for the EMA.

According to current Canadian guidances two evaluations have to be performed: one on raw data and another one corrected for measured content. The correction was dropped in 2010’s draft, but Appendix 1 Number of Subjects states:

Choose an expected true ratio of test over reference means (usually 100%, but consider potency differences between the test and reference products).

(my emphasis; tables give expected T/R-ratios up to -15% and +20%)

You are right with the [image] FDA (2003):

The drug content of the test product cannot differ from that of the reference listed product by more than 5 percent.


❝ The regulatory authorities will not accept BE study with the difference of 5% b/w test and reference batch.


See above.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
171 visitors (0 registered, 171 guests [including 19 identified bots]).
Forum time: 23:56 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5